Form 4: Corcept Therapeutics Chief Development Officer Sells Shares Under Pre-Arranged Plan

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 100 shares of common stock on July 1, 2025, after exercising stock options, as part of a pre-arranged 10b5-1 plan.

Summary

• William Guyer, the Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported transactions involving the company's common stock.
• On July 1, 2025, Guyer exercised stock options to acquire 100 shares of common stock at an exercise price of $21.65 per share.
• Concurrently, Guyer disposed of 100 shares of common stock through a sale at a price of $73.505 per share.
• The sale transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on November 27, 2024.
• Following these reported transactions, Guyer directly holds 5,487 shares of common stock.
• Guyer also continues to beneficially own 389,900 stock options, which are fully exercisable.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While an insider sale occurred, it was a small volume and executed under a pre-arranged 10b5-1 plan, which is a standard practice for managing insider equity. The significant profit realized from the option exercise is a positive for the individual.

Positives

• The sale price of $73.505 per share is significantly higher than the option exercise price of $21.65 per share, indicating a substantial profit for the Chief Development Officer on the exercised shares.
• The transaction was conducted under a Rule 10b5-1 plan, which suggests the sale was pre-scheduled and not based on immediate, non-public information, reducing concerns about opportunistic insider trading.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though the small volume of 100 shares mitigates this concern.

Future Outlook

NA

Industry Context

This document reports a routine insider transaction for Corcept Therapeutics, which is common across all industries for publicly traded companies. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May note the insider sale, but the small volume and 10b5-1 plan suggest it is a routine liquidity event rather than a signal of negative company prospects.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Transaction, Stock Options, Rule 10b5-1, William Guyer, Chief Development Officer, Equity Sale